Key Market Indicator:
F&G: 25
25.065,70 NASDAQ · 47.209,50 DOW · 6.746,95 S&P · 4.082,28 Gold · 63,89 BRENT

One Community. One Spirit. N#1 Broker.
all asset classes · all possibilities

Switch View
Hedge the Peak | Protect your Profits
© PR Newswire
15.09.2025
ISIN: CA23126M1023
Curaleaf Holdings Inc
CURA
LISTED
TSX
Curaleaf Expands Retail Footprint with Dispensary Openings in Florida and Ohio
Article
News Preview
New locations in Apopka, Florida and Girard, Ohio bring Curaleaf's nationwide store count to 157 STAMFORD, Conn., Sept. 15, 2025 /CNW/ -- Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer cannabis products, today announced the opening of two new dispensaries; Curaleaf Ap...
Themefolio
Profiler
Peergroup
© BusinessWire
15.09.2025
ISIN: US92790C1045
Viridian Therapeutics Inc
VRDN
LISTED
NASDAQ
Viridian Therapeutics Announces Completion of Enrollment in both REVEAL Clinical Trials and Positive Portfolio Updates
Article
News Preview
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today announced that enrollment is complete in REVEAL-1 and REVEAL-2, phase 3 clinical trials for VRDN-003 in patients with active and chronic TED, respectively....
Themefolio
Profiler
Peergroup
© PR Newswire
15.09.2025
ISIN: US50015M1099
Kodiak Sciences Inc
KOD
LISTED
NASDAQ
New data for Kodiak's KSI-101 from the APEX study reinforce its clinically meaningful vision gains and rapid retinal drying in macular edema secondary to inflammation (MESI)
Article
News Preview
Meaningful vision gains are rapidly achieved as early as week 4 and more than half of patients in the top two dose levels improved 3-lines or more on the eye chart (≥15 letter gain)A single dose of KSI-101 resulted in the majority of patients achieving resolution of intra-retinal and sub-retinal fluid and over 90% of patients achieved retinal dry...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
More Info
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© PR Newswire
15.09.2025
ISIN: US05350V1061
Avanos Medical Inc
AVNS
LISTED
NYSE
Avanos Medical Acquires Nexus Medical to Strengthen Nutrition and Medication Delivery in Critical Care
Article
News Preview
ALPHARETTA, Ga., Sept. 15, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS), a leading medical technology company, today announced the acquisition of Nexus Medical, LLC, a privately held medical device company based in Lenexa, Kansas....
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
15.09.2025
ISIN: CA39986R1064
Grown Rogue International Inc.
GRIN
LISTED
CSE
Grown Rogue Expands Senior Credit Facility by US$5 Million
Article
News Preview
Brings Total Facility to US$12 Million; Proceeds to Support Growth Initiatives MEDFORD, Ore., Sept. 15, 2025 /CNW/ - Grown Rogue International Inc. ("Grown Rogue" or the "Company") (CSE: GRIN) (OTC: GRUSF), a flower-forward cannabis company combining craft values with disciplined execution, today announced it has secured an incremental US$5 milli...
Themefolio
Profiler
Peergroup
© BusinessWire
15.09.2025
ISIN: CA1380357048
Canopy Growth Corp
CGC
LISTED
NASDAQ
Canopy Growth Strengthens Balance Sheet with Early US$25 Million Term Loan Prepayment
Article
News Preview
Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, announced today that it completed an early prepayment of US$25 million (the “Prepayment”) against the Company’s senior secured term loan (the “Term Loan”). The Co...
Themefolio
Profiler
Peergroup
© BusinessWire
15.09.2025
ISIN: US58933Y1055
Merck & Co Inc
MRK
LISTED
NYSE
Raludotatug Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with CDH6 Expressing Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancers Previously Treated with Bevacizumab
Article
News Preview
Raludotatug deruxtecan (R-DXd) has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with platinum-resistant epithelial ovarian, primary peritoneal or fallopian tube cancers expressing CDH6 who have received prior treatment with bevacizumab. Raludotatug deruxtec...
Themefolio
Profiler
Peergroup
© BusinessWire
15.09.2025
ISIN: JE00BYSS4X48
Novocure Ltd
NVCR
LISTED
NASDAQ
Novocure’s Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC)
Article
News Preview
Novocure (NASDAQ: NVCR) announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved Optune Lua® for concurrent use with PD-1/PD-L1 inhibitors for the treatment of adult patients with unresectable advanced/recurrent non-small cell lung cancer (NSCLC) who have progressed on or after platinum-based chemotherapy. “With the Mi...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.09.2025
ISIN: US29089Q1058
Emergent BioSolutions Inc
EBS
LISTED
NYSE
Emergent BioSolutions Secures $17 Million Contract Modification for Oral Suspension TEMBEXA® (brincidofovir), a Smallpox Antiviral, and Strengthens Overall U.S. Supply Chain
Article
News Preview
GAITHERSBURG, Md., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received a $17 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.09.2025
ISIN: CA82621K1021
Sienna Senior Living Inc
SIA
LISTED
TSX
Sienna Announces September Dividend
Article
News Preview
MARKHAM, Ontario, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“Sienna” or the “Company”) (TSX: SIA) today announced a dividend of $0.078 per common share of the Company (each, a “Common Share”) for the month of September 2025, representing $0.936 per Common Share on an annualized basis....
Themefolio
Profiler
Peergroup
© Globe Newswire
15.09.2025
ISIN: AU000000ACW3
Actinogen Medical Limited
ACW
LISTED
ASX
Actinogen achieves agreement with the FDA in a Type C meeting on the manufacturing, clinical and nonclinical activities required for a future US marketing approval of Xanamem for Alzheimer’s disease
Article
News Preview
Current XanaMIA pivotal phase 2/3 trial on track for interim analysis in January 2026 and final results late 2026 with trial enrolment expected to close in Q4 2025 Current XanaMIA pivotal phase 2/3 trial on track for interim analysis in January 2026 and final results late 2026 with trial enrolment expected to close in Q4 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.09.2025
ISIN: US1276361086
Cadrenal Therapeutics, Inc.
CVKD
LISTED
NASDAQ
Cadrenal Therapeutics Enhances Anticoagulation Pipeline Through Acquisition of eXIthera’s Portfolio of Factor XIa Inhibitors
Article
News Preview
PONTE VEDRA, Fla., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the gaps in anticoagulation therapy, today announced the acquisition of the assets of eXIthera Pharmaceuticals (“eXIthera”), including its proprietary portfolio of investi...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
15.09.2025
ISIN: CA3018351047
Extendicare Inc
EXE
LISTED
TSX
Extendicare Announces September 2025 Dividend of C$0.042 per Share
Article
News Preview
MARKHAM, Ontario, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced that it has declared a cash dividend of C$0.042 per common share of the Company for the month of September 2025, which is payable on October 15, 2025 to shareholders of record at the close of business on September 30, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
15.09.2025
ISIN: US45782T1051
INmune Bio, Inc.
INMB
LISTED
NASDAQ
INmune Bio Announces Successful Completion of First Commercial Pilot-Scale Manufacturing Run of CORDStrom™ at CGT Catapult
Article
News Preview
BOCA RATON, Fla., Sept. 15, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (“INmune” or “the Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced the successful completion of its first full-scale pilot commercial...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.09.2025
ISIN: US59503A2042
Microbot Medical Inc.
MBOT
LISTED
NASDAQ
Microbot Medical Announces Exercise of Outstanding Preferred Investment Options for Up to $92.2 Million in Gross Proceeds
Article
News Preview
$25.2 million in first closing and $4 million in second closing, with up to an additional approximately $63 million of potential aggregate gross proceeds upon the exercise in full of short-term preferred investment options $25.2 million in first closing and $4 million in second closing, with up to an additional approximately $63 million of potentia...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.09.2025
ISIN: US5011471027
Krystal Biotech Inc
KRYS
LISTED
NASDAQ
Krystal Biotech Announces FDA Approval of Updated VYJUVEK® Label
Article
News Preview
Revised label allows treatment of DEB patients from birth...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.09.2025
ISIN: DK0062498333
Novo Nordisk A/S
NOVO B
LISTED
CPH
EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
Article
News Preview
Bagsværd, Denmark, 15 September 2025 – Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has approved an update to the Rybelsus® (oral semaglutide) label to reflect the cardiovascular benefits seen in the SOUL trial. SOUL was a phase 3b trial carried out to evaluate the eff...
Themefolio
Profiler
Peergroup
© Newsfile
15.09.2025
ISIN: CA41138T1057
Happy Belly Food Group Inc.
HBFG
LISTED
CSE
Happy Belly Food Group's Heal Wellness QSR Announces the Signing of a Franchise Agreement for Collingwood, Ontario
Article
News Preview
Toronto, Ontario--(Newsfile Corp. - September 15, 2025) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leader in acquiring and scaling emerging food brands is pleased to announce that Heal Wellness has signed a franchise agreement for the Collingwood area of Ontario. Heal Wellness ("Heal") is a quick-se...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
15.09.2025
ISIN: US6986681004
PAO Group, Inc.
PAOG
LISTED
OTC
PAO Group Inc Announces New CEO James Schramm
Article
News Preview
OMAHA, NE / ACCESS Newswire / September 15, 2025 / PAO Group, Inc. (OTC:PAOG), today announced the appointment of James Schramm as Chief Executive Officer of PAO Group, Inc. In a meeting of the Board of Directors, Mr. Schramm was named CEO and James C DiPrima will step down as CEO and remain Chief Financial Officer. The action was taken in response...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.09.2025
ISIN: US6979471090
Palvella Therapeutics Inc
PVLA
LISTED
NASDAQ
Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of QTORIN™ Rapamycin for Cutaneous Venous Malformations
Article
News Preview
Phase 2 TOIVA trial successfully met recruitment target, enrolling 16 subjects at leading vascular anomaly centers; top-line data expected in mid-December 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.09.2025
ISIN: US02155H1014
Altimmune, Inc.
ALT
LISTED
NASDAQ
Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer
Article
News Preview
GAITHERSBURG, Md., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced the appointment of Linda M. Richardson to the role of Chief Commercial Officer, effective September 16, 2025. Ms. R...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.09.2025
ISIN: US02155X2053
Alterity Therapeutics Limited
ATHE
LISTED
NASDAQ
Alterity Therapeutics Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting
Article
News Preview
ATH434 demonstrated clinically meaningful efficacy in modifying disease progression and was well tolerated at both 50 and 75 mg doses ATH434 demonstrated clinically meaningful efficacy in modifying disease progression and was well tolerated at both 50 and 75 mg doses...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.09.2025
ISIN: US13471N3008
Can-Fite BioPharma Ltd.
CANF
LISTED
XASE
Can-Fite Reports Complete Resolution of Esophageal Varices in Decompensated Cirrhosis Patient Treated with Namodenoson
Article
News Preview
Ramat Gan, Israel, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced a significant new clinical finding under its compassionate use program in decompensated...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.09.2025
ISIN: US4158581094
Harrow Inc
HROW
LISTED
NASDAQ
Harrow Announces Agenda and Speakers for Investor & Analyst Day
Article
News Preview
NASHVILLE, Tenn., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the agenda for its upcoming Investor & Analyst Day on Friday, September 26, from 11:30 a.m. ET to 3 p.m. ET in New York. The event will also be webcast live and instru...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.09.2025
ISIN: US61225M1027
Monte Rosa Therapeutics Inc
GLUE
LISTED
NASDAQ
Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases
Article
News Preview
Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
15.09.2025
ISIN: US74366E1029
Protagonist Therapeutics Inc
PTGX
LISTED
NASDAQ
Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025
Article
News Preview
NEWARK, CALIFORNIA / ACCESS Newswire / September 15, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that data from the Phase 2b ANTHEM-UC study with icotrokinra in ulcerative colitis will be the focus of a brief oral presentation at the United European Gastroenterology Week 2025 being held in Be...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.09.2025
ISIN: US67577C1053
Ocugen Inc
OCGN
LISTED
NASDAQ
Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea
Article
News Preview
MALVERN, Pa., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today executed a licensing agreement with Kwangdong Pharmaceutical, Co., Ltd., (“Kwangdong”) one of the leading pharmaceutical companies in Korea, for the exclusive K...
Themefolio
Profiler
Peergroup
© PR Newswire
15.09.2025
ISIN: US02157Q1094
Alto Neuroscience, Inc.
ANRO
LISTED
NYSE
Alto Neuroscience, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ANRO
Article
News Preview
LOS ANGELES, Sept. 15, 2025 /PRNewswire/ -- The DJS Law Group  reminds investors of a class action lawsuit against Alto Neuroscience, Inc. ("Alto " or "the Company") (NYSE: ANRO ) for violations of the federal securities laws. Shareholders who purchased shares of Alto during the class period listed are encouraged to contact the firm regarding po...
Themefolio
Profiler
Peergroup
© PR Newswire
15.09.2025
ISIN: US02157Q1094
Alto Neuroscience, Inc.
ANRO
LISTED
NYSE
ANRO Investors Have Opportunity to Lead Alto Neuroscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Article
News Preview
LOS ANGELES, Sept. 15, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the firm has filed a class action lawsuit against Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE: ANRO) for violations of the federal securities laws....
Themefolio
Profiler
Peergroup
© BusinessWire
15.09.2025
ISIN: US2521311074
Dexcom Inc
DXCM
LISTED
NASDAQ
Dexcom Spotlights Upcoming Feature Launches, Improved Health Outcomes and Cost-Effectiveness With Dexcom Glucose Biosensing at EASD 2025
Article
News Preview
DexCom, Inc. (Nasdaq: DXCM), a global leader in glucose biosensing, will present new product features and a compilation of new evidence that shows the benefits of its glucose biosensing technology for people with all types of diabetes at the upcoming 61st annual European Association for the Study of Diabetes (EASD) Conference. This press release...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
15.09.2025
ISIN: US29415J1060
enVVeno Medical Corporation
NVNO
LISTED
NASDAQ
enVVeno Medical Updates Regulatory Status of VenoValve(R)
Article
News Preview
IRVINE, CA / ACCESS Newswire / September 15, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that it will file a request for supervisory appeal of the not-approvable letter from the Center for Devices...
Themefolio
Profiler
Peergroup
© BusinessWire
15.09.2025
ISIN: US71377E1055
Performant Healthcare, Inc.
PHLT
LISTED
NASDAQ
Shareholder Alert: The Ademi Firm Continues to Investigate Whether Performant Healthcare Inc. is Obtaining a Fair Price for its Public Shareholders
Article
News Preview
The Ademi Firm continues to investigate Performant (NASDAQ: PHLT) for possible breaches of fiduciary duty and other violations of law in its transaction with Machinify. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligatio...
Themefolio
Profiler
Peergroup
© BusinessWire
15.09.2025
ISIN: US8523123052
STAAR Surgical Co
STAA
LISTED
NASDAQ
Shareholder Alert: The Ademi Firm Continues to Investigate Whether STAAR Surgical Company Is Obtaining a Fair Price for Its Public Shareholders
Article
News Preview
The Ademi Firm continues to investigate STAAR (NASDAQ: STAA) for possible breaches of fiduciary duty and other violations of law in its transaction with Alcon Inc. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
15.09.2025
ISIN: US60785L2079
Modular Medical, Inc.
MODD
LISTED
NASDAQ
Modular Medical Receives IRB Approval for Pivot Insulin Delivery System Feasibility Study
Article
News Preview
-Study to Evaluate Usability and Extended Wear for Next-Generation Tubeless Patch Pump SAN DIEGO, CA / ACCESS Newswire / September 15, 2025 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), a leader in innovative insulin delivery technology targeting the $3 billion adult "almost-pumpers" diabe...
Themefolio
Profiler
Peergroup
© BusinessWire
15.09.2025
ISIN: US14179K1016
CARGO Therapeutics Inc
CRGX
LISTED
NASDAQ
Shareholder Alert: The Ademi Firm Continues to Investigate Whether CARGO Therapeutics, Inc. is Obtaining a Fair Price for its Public Shareholders
Article
News Preview
The Ademi Firm is investigating CARGO (NASDAQ: CRGX) for possible breaches of fiduciary duty and other violations of law in its transaction with Concentra Biosciences. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation...
Themefolio
Profiler
Peergroup
© BusinessWire
15.09.2025
ISIN: US09627Y1091
Blueprint Medicines Corp
BPMC
LISTED
NASDAQ
Shareholder Alert: The Ademi Firm Continues to Investigate the Blueprint Medicines Corporation Transaction
Article
News Preview
The Ademi Firm is investigating Blueprint (Nasdaq: BPMC) and its transaction with Sanofi. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, Blueprint insiders received substantial benefit...
Themefolio
Profiler
Peergroup
© EQS Newswire
15.09.2025
ISIN: CH1330780979
Curatis Holding AG
CURN
LISTED
SIX
Double-digit growth in core business and development milestone achieved for C-PTBE-01
Article
News Preview
Ad hoc announcement pursuant to Art. 53 LR Liestal, Switzerland, 15 September 2025: Curatis Holding AG (SIX:CURN) reports revenues of CHF 5.2m for H1 2025, a like for like yoy growth of 14% vs 6 months of revenues of Curatis AG in 2024. In addition, Curatis was able to sign a significant partnership with Phoenix Labs, Ireland, adding 4 products tha......
Themefolio
Profiler
Peergroup
© EQS Newswire
15.09.2025
ISIN: CH0012549785
Sonova Holding AG
SOON
LISTED
SIX
Eric Bernard takes over as Sonova CEO effective September 15, 2025
Article
News Preview
Sonova Holding AG / Key word(s): Personnel Eric Bernard takes over as Sonova CEO effective September 15, 2025 15.09.2025 / 07:00 CET/CEST Group Media & Investor Release Staefa (Switzerland), September 15, 2025 – Sonova Holding AG (SWX: SOON), a leading provider of innovative hearing care solutions, announces that Er......
Themefolio
Profiler
Peergroup
© EQS Newswire
15.09.2025
ISIN: CH0012549785
Sonova Holding AG
SOON
LISTED
SIX
Eric Bernard übernimmt als Sonova CEO per 15. September 2025
Article
News Preview
Sonova Holding AG / Schlagwort(e): Personalie Eric Bernard übernimmt als Sonova CEO per 15. September 2025 15.09.2025 / 07:00 CET/CEST Group Media & Investor Release Stäfa (Schweiz), 15. September 2025 – Sonova Holding AG (SWX: SOON), ein führender Anbieter innovativer Hörlösungen, gibt bekannt, dass Eric Bernard he......
Themefolio
Profiler
Peergroup
© BusinessWire
15.09.2025
ISIN: FR0010331421
Innate Pharma SA
IPH
LISTED
EURONEXT
Innate Pharma Announces Its Participation in the 25th Edition of the European Midcap Event
Article
News Preview
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that Frédéric Lombard, Chief financial Officer of the Company, will participate in the 25th edition of the European Midcap Event being held from September 30 to October 1, 2025 in Paris, France. The European Midcap Event is a key g...
Themefolio
Profiler
Peergroup
© BusinessWire
15.09.2025
ISIN: CH1330780979
Curatis Holding AG
CURN
LISTED
SIX
Curatis: Double-Digit Growth in Core Business and Development Milestone Achieved for C-PTBE-01
Article
News Preview
Curatis Holding AG (SIX:CURN) reports revenues of CHF 5.2m for H1 2025, a like for like yoy growth of 14% vs 6 months of revenues of Curatis AG in 2024. In addition, Curatis was able to sign a significant partnership with Phoenix Labs, Ireland, adding 4 products that generated approximately CHF 5m of revenues in 2024. The loss for the period amoun...
Themefolio
Profiler
Peergroup
© PR Newswire
15.09.2025
ISIN: KYG0146B1032
Akeso, Inc.
9926
LISTED
HKSE
Akeso Announces First Patient Dose in Global Registrational Trial of Cadonilimab (PD-1/CTLA-4) for PD-1 Treatment-Resistant Hepatocellular Carcinoma
Article
News Preview
HONG KONG, Sept. 15, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its global, multicenter, randomized Phase II registrational trial (COMPASSION-36/AK104-225). The trial will evaluate cadonilimab, Akeso's first-in-class PD-1/CTLA-4 bispecific antibody, in combination with...
Themefolio
Profiler
Peergroup
© PR Newswire
15.09.2025
ISIN: AU000000ADR1
Adherium Limited
ADR
LISTED
ASX
New Data, iCARE Study: Hailie® Smartinhaler® Powers Unprecedented Medication Adherence in Patients with COPD and Asthma
Article
News Preview
Highlights: Up to 235% increase in real-world adherence compared to published norms (20–40%), across ~850 chronic obstructive pulmonary disease (COPD) and asthma patients.>60% patients achieved an average two-week baseline adherence with ~4 in 10 patients reaching the critical threshold of >80% adherence, a level associated with 50% fewer e...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
15.09.2025
ISIN: CA98421R1055
XPhyto Therapeutics Corp.
XPHY
LISTED
CSE
BioNxt Advances Semaglutide Oral Dissolvable Film (ODF) Program with Successful Proof-of-Concept and Prototype Development
Article
News Preview
VANCOUVER, BC / ACCESS Newswire / September 15, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:XPHYF)(FSE:4XT) is pleased to announce the successful completion of proof-of-concept trials for its Semaglutide oral dissolvable film ("ODF") program at Vektor Pharma TF GmbH ("Vektor Pharma&qu...
Themefolio
Profiler
Peergroup
© PR Newswire
15.09.2025
ISIN: KR7145020004
Hugel, Inc.
145020
LISTED
KOE
Hugel hosts global H.E.L.F. symposium, marking 15 years of botulinum toxin Letybo
Article
News Preview
- It highlights K-beauty values and global medical aesthetic trends- The event welcomes around 220 professionals from more than 25 countries - The program features sessions on toxin, hyaluronic acid filler, and suture SEOUL, South Korea, Sept. 14, 2025 /PRNewswire/ -- Hugel Inc., a leading global medical aesthetics company, hosted its global medi...
Themefolio
Profiler
Peergroup
© PR Newswire
15.09.2025
ISIN: JP3435750009
M3 Inc
MTHRF
LISTED
OTC
EverBridge Group and Cosmotec Forge Landmark Partnership
Article
News Preview
SHANGHAI, Sept. 15, 2025 /PRNewswire/ -- EverBridge Group announced an Exclusive Commercialization Partnership with Cosmotec Inc. (a Wholly Owned Subsidiary of M3, Inc.; TSE: 2413) for the Japanese market. This strategic collaboration underscores EverBridge Group's leadership in proprietary R&D, stringent regulatory compliance, and value-dri...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
15.09.2025
ISIN: GB00BP2C3V08
Genflow Biosciences Plc
GENF
LISTED
LSE
Genflow Signs CDAs with Animal Health Companies
Article
News Preview
Genflow Signs CDAs with Animal Health Companies to Advance Longevity Gene Therapy Platform LONDON, UK / ACCESS Newswire / September 15, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), the only publicly listed longevity company in Europe, today announces that it has signed two Confidential Dis...
Themefolio
Profiler
Peergroup
© PR Newswire
15.09.2025
ISIN: KYG3224E1061
Everest Medicines Limited
1952
LISTED
HKSE
Real-World Evidence of NEFECON® to Be Presented in Seven New Abstracts at the 18th International lgAN Symposium
Article
News Preview
7 new NEFECON® real-world evidence abstracts will be presented at the 18th International lgA Nephropathy Symposium (IIgANN 2025).The newly released results, based on clinical practices at several leading hospitals in China, offer a comprehensive overview of the efficacy and safety of NEFECON® in the treatment of IgA nephropathy (IgAN). NEFECON® c...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.09.2025
ISIN: AU000000AVH4
Avita Medical Inc.
AVH
LISTED
ASX
AVITA Medical Receives CE Mark for RECELL® GO, Enabling Commercialization Across Europe
Article
News Preview
AVITA Medical has received the CE Mark for RECELL GO. This mark enables AVITA to begin commercializing RECELL GO across Europe....
Themefolio
Profiler
Peergroup
© PR Newswire
14.09.2025
ISIN: US81684M1045
Semler Scientific Inc
SMLR
LISTED
NASDAQ
SMLR Investors Have Opportunity to Lead Semler Scientific, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm
Article
News Preview
NEW YORK, Sept. 14, 2025 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Semler Scientific, Inc. (NASDAQ: SMLR) between March 10, 2021 and April 15, 2025, both dates incl...
Themefolio
Profiler
Peergroup
© PR Newswire
14.09.2025
ISIN: US5165441032
Lantheus Holdings Inc
LNTH
LISTED
NASDAQ
LNTH INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Lantheus Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Article
News Preview
NEW YORK, Sept. 14, 2025 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lantheus Holdings, Inc. ("Lantheus" or "the Company") (NASDAQ: LNTH) and certain of its officers....
Themefolio
Profiler
Peergroup
© PR Newswire
14.09.2025
ISIN: US5165441032
Lantheus Holdings Inc
LNTH
LISTED
NASDAQ
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lantheus
Article
News Preview
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Lantheus To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Lantheus between February 26, 2025 and August 5, 2025 and would like to discuss your legal rights, call Faruq...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.09.2025
ISIN: US61023L1089
Monopar Therapeutics Inc
MNPR
LISTED
NASDAQ
Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual Meeting
Article
News Preview
WILMETTE, Ill., Sept. 14, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that new data on the long-term neurological efficacy and safety of its investigational therapy...
Themefolio
Profiler
Peergroup
© BusinessWire
14.09.2025
ISIN: US02157Q1094
Alto Neuroscience, Inc.
ANRO
LISTED
NYSE
ANRO Deadline: Rosen Law Firm Urges Alto Neuroscience, Inc. (NYSE: ANRO) Stockholders to Contact the Firm for Information About Their Rights
Article
News Preview
Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of common stock of Alto Neuroscience, Inc. (NYSE: ANRO): (i) pursuant and/or traceable to Alto’s initial public offering conducted on or about February 2, 2024 (the “IPO”); and/or (ii) securities between February 2,...
Themefolio
Profiler
Peergroup
© BusinessWire
13.09.2025
ISIN: US6404911066
Neogen Corp
NEOG
LISTED
NASDAQ
NEOG Deadline: Rosen Law Firm Urges Neogen Corporation (NASDAQ: NEOG) Stockholders to Contact the Firm for Information About Their Rights
Article
News Preview
Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of common stock of Neogen Corporation (NASDAQ: NEOG) between January 5, 2023 and June 3, 2025. Neogen describes itself as a “food safety company that manufactures and markets products and services dedicated to food a...
Themefolio
Profiler
Peergroup
© PR Newswire
13.09.2025
ISIN: US8342033094
Soleno Therapeutics Inc
SLNO
LISTED
NASDAQ
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc.- SLNO
Article
News Preview
NEW YORK, Sept. 13, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Themefolio
Profiler
Peergroup
© PR Newswire
13.09.2025
ISIN: US05463X1063
AxoGen Inc
AXGN
LISTED
NASDAQ
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN
Article
News Preview
NEW YORK, Sept. 13, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Axogen, Inc. ("Axogen" or the "Company") (NASDAQ: AXGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Themefolio
Profiler
Peergroup
© PR Newswire
13.09.2025
ISIN: US00847X1046
Agios Pharmaceuticals Inc
AGIO
LISTED
NASDAQ
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
Article
News Preview
NEW YORK, Sept. 13, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. ("Agios" or the "Company") (NASDAQ: AGIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Themefolio
Profiler
Peergroup
© PR Newswire
13.09.2025
ISIN: US90466Y1038
Unicycive Therapeutics, Inc.
UNCY
LISTED
NASDAQ
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive Therapeutics
Article
News Preview
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Unicycive To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Unicycive between March 29, 2024 and June 27, 2025 and would like to discuss your legal rights, call Faruqi...
Themefolio
Profiler
Peergroup
© PR Newswire
13.09.2025
ISIN: US67079U3068
Nutex Health Inc
NUTX
LISTED
NASDAQ
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Nutex Health
Article
News Preview
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Nutex To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Nutex between August 8, 2024 and August 15, 2025 and would like to discuss your legal rights, call Faruqi &...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
Indices
DAX, DOW, S&P, FTSE...
Realtime Trading
With & without leverage
Currencies
EUR, USD, JPY, BRL, GBP ....
50 FX-Pairs
Top Conditions, Tied spreads, Mini/Micro
Commodities
Brent, WTI, Coffee, Wheat....
Long & Short
Crude oil, Agricultural & more
Metals
Gold, Silver, Palladium, Platinum
Hedging
Soft-,Heavy-, Precious Metals
Stocks & ETF
TSLA, NFLX, NVDA, MSFT, AAPL ....
Leveraged Equity Trading
USA, Europe, Asia
More information, click here

More sector specific news

Your Press Release is missing or you want share news over GICS11? Drop us a line.

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2025 Select Sector SPDRs
* * *
More Sector related Investment Ideas
XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2025 WEBs Investments ETFs
About the newsfeed
#1
What types of information are provided on this portal - and what purpose does it serve?
The portal provides structured, stock market-relevant company information that is specifically assigned to a particular economic sector. The focus is on current announcements from official NewsWire sources, supplemented by company profiles, filter options by sector and sector-specific research aids. The aim is to offer an interested group of people a systematically structured research environment that improves their understanding of sector developments and corporate strategies.
#2
Why are companies categorized according to a certain system?
Financial markets consist of thousands of listed companies with very different business models. In order to create transparency and comparability, companies worldwide are assigned to standardized classifications. These classifications help investors to better analyze markets, identify sector-specific trends and make more targeted investment decisions.
#3
What classification standards exist for grouping companies?
There are various industry classifications that are used depending on the region or application. The best known include GICS (Global Industry Classification Standard), ICB (Industry Classification Benchmark), NAICS (North American Industry Classification System) and TRBC (Thomson Reuters Business Classification). Most institutional investors and ETFs worldwide use GICS or ICB as a benchmark.
#4
What classification standard is this financial information portal based on?
The portal uses the Global Industry Classification Standard (GICS), which was jointly developed by MSCI and S&P Dow Jones Indices. GICS is widely used in the institutional financial world and forms the basis for many global equity indices, ETFs and research systems.
#5
What exactly does GICS mean - and how is the system structured?
GICS stands for Global Industry Classification Standard. It is a hierarchical structure that divides listed companies worldwide into four levels: Sector, Industry Group, Industry Sector and Sub-Industry. In total, the system comprises 11 main sectors, over 60 industries and more than 150 sub-categories. It allows a consistent, internationally comparable analysis of economic activities.
#6
Why is GICS important in the financial world?
GICS offers a standardized language for investment decisions. It makes it possible to compare companies with similar business models - regardless of country, stock exchange or company size. Many investment funds, indices and research houses use GICS as a basis for portfolio construction, risk analysis or market screening. This means that it also makes sense for private investors to use this structure as a guide.
#7
Who decides which GICS sector a company is assigned to?
The allocation is made by the index providers MSCI and S&P Dow Jones on the basis of a company's main business segment. The decisive factor is the segment from which the company generates the majority of its sales or operating profit. Changes in the business model or strategic realignments can lead to a company being assigned to a different industry or even a different sector.
#8
What is meant by the GICS sector "Materials"?

The GICS "Materials" sector comprises companies that are active in the production, processing or refinement of raw materials. This includes industries such as chemicals, building materials, paper & forest products and the entire metallurgical and mining industry. The sector is highly cyclical and is particularly sensitive to economic fluctuations and changes in global demand.

#9
Which companies typically belong to the Materials sector?
Typical representatives are international groups from the areas of chemicals production (e.g. BASF), precious metal mining (e.g. Barrick Gold), building materials production (e.g. Heidelberg Materials) or industrial gases (e.g. Linde). The shares of these companies are often heavily dependent on commodity prices and play a central role in industrial value chains.
#10
Where does the company news on this page come from?
The news is based on verified and publicly available sources such as BusinessWire, GlobeNewswire, PR Newswire, EQS, Newsfile, ACCESSNewswire and other NewsWire services. These platforms are used by listed companies to publish mandatory ad hoc announcements, financial reports or strategic developments. All content is prepared in a structured manner and, if a corresponding categorization is possible, brought together in industry-specific clusters.
#11
How is the sector-specific mapping of messages carried out?
Categorization is based on structured metadata (e.g. ISIN, ticker, sector classification) and a combination of keyword analysis and GICS mapping. This ensures that all news is assigned to the correct sector and - if available - the correct sub-sector.
#12
Why is the materials sector particularly interesting for investors?
The Materials sector is closely linked to global industrial production and offers both cyclical growth opportunities and hedging opportunities against inflation and raw material shortages. In addition, many companies in this sector play a key role in future topics such as electromobility, the energy transition and sustainable building materials.
#13
What distinguishes this project from traditional financial information portals?
In contrast to generic portals, this project focuses exclusively and specifically on a particular sector. The advantage for interested investors: Sector-specific information, news, market movements and company profiles can be filtered and analyzed in a more targeted manner. This enables more in-depth research and greater relevance for thematic investment decisions.
#14
Are smaller companies also represented here or only large corporations?
The newsfeed takes into account both large caps and mid and small caps. As a clear mapping criterion is required in order to enable the most precise possible allocation to a cluster, the ISIN of the listed company is generally used for this purpose, provided that this can be made available or mapped via corresponding newsfeed parameters.
#15
How up-to-date are the displayed messages?
The content is updated regularly. The publication follows the publications of the information source, the NewsWire feeds of the underlying distributors. Incoming reports are automatically processed, classified and displayed on the page. Timestamps and source information ensure maximum transparency.
#16
Can I also filter the news by sub-sector?
Yes, this is a central feature of the site. Within a main sector, you can filter specifically for sub-sectors such as "Metals & Mining". For particularly popular industries or developments within a meta-sector, it is possible to deviate from standard clusters. Special categories with particular information value enable thematic analyses to be carried out even more precisely.
#17
Are there plans to process other metasectors in a similar way?
Yes, this financial information portal is part of an extensive project in which separate information portals are being created for all the main sectors. The aim is to provide investors with a systematic, sector-based research tool - regardless of index affiliation or provider perspective.
#18
Why do companies publish announcements via NewsWire services at all?
NewsWire services such as BusinessWire or PR Newswire fulfill a regulatory function: they enable companies to publish price-sensitive information publicly and without discrimination. In many countries, the use of such services is a prerequisite for fulfilling publication obligations under capital market law. They also enable companies to reach the media, analysts and investors in a targeted manner.
#19
Can private or inactive companies also appear in such notifications?
Generally not. The platform focuses exclusively on listed companies whose disclosures are based on regulatory requirements or corporate strategy measures. Although private or unlisted companies occasionally publish announcements, these are not systematically processed or classified here.
#20
What happens when a company changes its business model - does its sector classification also change?
Yes, as a rule - but not automatically. The responsible classification institutes (e.g. MSCI and S&P for GICS) regularly check the relevance and consistency of the classifications. If there is a significant change in a company's sales or profit profile, it may be reclassified to a different industry or even a different sector. This usually takes place after fixed review cycles or upon request.
#21
How is it ensured that a company is correctly categorized if it is active in several business areas?
The categorization is based on the dominant sales segment. If a company is active in several sectors but generates 70% of its turnover with chemical products, for example, it is assigned to the GICS sector "Materials" - even if it also has activities in the energy or transportation sector. In borderline cases, additional qualitative assessment criteria apply.
#22
Are there any legal risks in the further use of the displayed content?
The content comes from public sources, but is partially subject to copyright protection - particularly with regard to text structure and layout. The excerpts and links provided on this portal are made within the scope of permitted use (e.g. right to quote or editorial processing). However, commercial use by third parties is not permitted without the express permission of the original providers.
#23
Who can I contact if I have general questions or legal concerns?
A central contact point is available for general inquiries, information on company recordings, compliance issues or copyright-relevant aspects. In rare cases, for example in the case of erroneously published information or justified requests for deletion, a review and, if necessary, removal from the public feed can take place. Please only use the official contact option in the legal notice or at the bottom of the page.
#24
Is advertising or third-party content also displayed on the portal?
Yes, in defined areas the portal can display advertising content or product-specific information from third parties - for example on sector-related financial services, research offers or trading platforms. This content is clearly marked as advertising or partner information and is separate from the editorial or automatically processed company news.
#26
Can I give feedback on the platform or submit suggestions?
Absolutely - feedback is expressly welcome. The platform is an open information service that is continuously being developed. Comments on functionality, data quality, usability or thematic extensions help to optimize the service for the benefit of users. You can submit your suggestions informally via the contact page or special feedback forms.
#27
I am an information provider - can I cooperate with the portal?
Yes, the portal is open to content-related, technical or editorial cooperation, provided that this contributes to the quality, relevance or dissemination of the offering. If you offer content, interfaces or services that could be useful in the context of stock market-related information, we would be pleased to hear from you. The platform offers flexible integration options and a professional environment for quality-assured content.
#28
Can the platform technology also be used for other applications or partners?
Yes, the platform is based on a modular, scalable infrastructure that can be adapted to different information contexts and industry models. Technical components such as data aggregation, structuring logic, classification mechanisms and semantic filters can also be made available for external projects or individual applications on request. Please contact us for cooperation or license models.
#29
Can the underlying company data also be licensed or reused?
Structured access to selected master data of listed companies - such as GICS mapping, ISIN mapping, news feeds or metadata filters - is generally possible. The offer is aimed in particular at information service providers, research platforms or data-driven financial applications. Data can be provided via defined interfaces (e.g. API) or exportable formats, depending on the intended use and license framework.
#30
What forms of cooperation with external partners are conceivable?
Basically open. Possible forms of cooperation range from technical integrations and shared data models to content syndication or white label solutions. Partnerships with institutions that are looking for access to quality-assured data, dynamically structured news or sector-specific analyses - for example in the FinTech, media or research environment - are particularly interesting. We look forward to hearing from business development or product management departments.
#31
Why does this portal differ technically and conceptually from other information offerings?
Because no one from outside the industry is trying to understand the financial market here - but because the know-how comes from the heart of the financial world. The technical platform was developed by a team that combines in-depth market knowledge with innovative system design. The result: information architecture with real relevance, not shop window technology.
#32
What makes the technical solution particularly interesting for operators of their own financial portals?
In addition to high adaptability, the platform impresses with its modular structure and the consistent implementation of industry-specific logic - from GICS mapping to metadata filtering. For providers who operate their own information portals, sector-specific data structures, news feeds or visualizations can be quickly integrated on this basis - either as a white label, API module or embedded solution.
#33
Why can a collaboration go beyond traditional development services?
Because we don't just program, we think: The technological implementation is based on a deep understanding of market cycles, regulations, data formats and investor needs. Anyone who cooperates with this platform benefits from a sparring partner at eye level - both technically and professionally. This creates added value that goes far beyond pure IT expertise.
#34
Note on copyright and the processing of original content
The corporate news presented on this information portal is based on publicly accessible sources such as BusinessWire, GlobeNewswire, PR Newswire or comparable news services. The content is processed as part of an automated or editorially supported structuring process without changing, shortening or reinterpreting the content of the original information. This is so-called "as is" information, the form and content of which corresponds to the originally published announcement. The rights to the original texts remain unrestrictedly with the respective publishers or copyright holders. This portal merely assumes a structural categorization and allocation within the framework of a news-journalistic offer. Independent commercial reuse, systematic reproduction or other use of the content by third parties is only permitted within the framework of the statutory provisions or with the consent of the copyright holder.
About GICS Health
GICS Health is part of the GICS Eleven information portfolio, which focuses primarily on information from listed companies in the health sector. The sector classification serves as a guide to navigate quickly and conveniently through the latest industry-specific news. Individual peer group clusters complement the news offering.
About GICS Eleven

GICS Eleven (G11, GICS11) bundles topic-specific content and enables quick access to relevant information thanks to its gate function. The project is largely based on the Global Industry Classification Standard (GICS®), which was developed by MSCI and Standard & Poor's and enables a breakdown into sectors. GICS® consists of 11 sectors, 24 industry branches, 69 industries and 158 sub-industries.

GICS® is a registered trademark of MSCI Inc. and S&P Dow Jones Indices.

Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Sunday, 16.11.2025, Calendar Week 46, 320th day of the year, 45 days remaining until EoY.